News < 1 2 3 >

CCC Diagnostics and the University of Maryland Awarded a Second Year of MIPS Funding

02/18/2008 – CCC Diagnostics and the University of Maryland have been awarded a second year of funding from the Maryland Industrial Partnerships in support of their project, “Clinical Studies of the Drug Response Indicator Test.” Article from the Baltimore Business Journal

DRIT Clinical Data Presented at 2008 ICACT Meeting

02/08/2008 – Dr. Katherine Tkaczuk of the University of Maryland Greenebaum Cancer Center gave an oral presentation describing CCC Diagnostics’ DRIT technology at the 19th International Congress on Anti-cancer Treatment in Paris, France.

CCC Diagnostics, LLC Presents Poster at San Diego AACR Conference

10/2007 – CCC Diagnostics, LLC was invited to present a poster at the AACR-Special Conference in Cancer Research: Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications in San Diego, CA.

The University of Maryland and CCC Diagnostics Receive $410,477 in MIPS Funding

02/2007 – Baltimore-based CCC Diagnostics, LLC and the University of Maryland, Baltimore received $410,477 for clinical studies of the company’s diagnostic service for personalized chemotherapy, which measures a tumor’s resistance to commonly used cancer drugs.
Excerpt University of Maryland Press Release

The University of Maryland and CCC Diagnostics Receive MIPS Funding

12/2006 – CCC Diagnostics and Dr. Katherine Tkaczuk of the University of Maryland Greenebaum Cancer Center have been selected to receive a Maryland Industrial Partnerships (MIPS) grant for their project, “Clinical Studies of the Drug Response Indicator Test.”

CCC Diagnostics Receives COSAT Funding

10/2006 – CCC Diagnostics, LLC has been chosen to receive funding from Johnson and Johnson’s Corporate Office of Science and Technology (COSAT) for development of the Drug Response Indicator Test. This funding will be administered as part of TEDCO’s Maryland Technology Transfer Fund (MTTF) award.

TEDCO Approves $75,000 Award to CCC Diagnostics, LLC

09/2006 – The Maryland Technology Development Corporation (TEDCO) has approved an award of $75,000 to CCC Diagnostics, LLC (CCCD) through the Maryland Technology Transfer Fund. The funding will support clinical studies of CCCD’s Drug Response Indicator Test (DRIT).

The Drug Response Indicator Test (DRIT) utilizes proprietary platform technology and delivers in one test a detailed profile of the tumor’s response rate to 5-7 FDA approved anticancer drugs. Armed with the advanced diagnostics, physicians are able to treat patients more effectively and with greater speed. CCCD’s commitment is to “saving lives and life savings.”